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Abstract. Background: Radiographic contrast agents
inhibit fibrinolysis, although by poorly defined path-
ways. The purpose of this study was to define specific
mechanisms by which contrast agents inhibit clot lysis.
Methods and Results: Diatrizoate (high osmolar ionic
agent), ioxaglate (low osmolar ionic), and ioversol
(nonionic) were studied in vitro. Diatrizoate inhibited
clot lysis by 81.30.6% vs. control (p<0.001). Ioxaglate
inhibited clot lysis by 41.711.9%, which was of border-
line significance (p¼0.07). Ioversol did not signifi-
cantly inhibit clot lysis (14.911.5% decrease vs.
control; p>0.3). Inhibition of fibrinolysis was not
explained by the high osmolarities of contrast agents,
by their iodine content, or by their effects on the
amidolytic activities of t-PA, urokinase, or plasmin.
However, plasminogen activation by t-PA, urokinase,
or streptokinase was significantly inhibited by
contrast agents. Diatrizoate, ioxaglate, and ioversol
inhibited plasminogen binding to plasma clots by
514% (p<0.001), 30.14% (p<0.01), and 19.47%
(p¼0.07), respectively. Plasma clots formed in the
presence of contrast agents were resistant to lysis by
plasmin. Diatrizoate produced the most potent effect,
inhibiting clot lysis by 405.7% (p<0.03). Contrast
agents did not inhibit plasminogen binding to fibrin
or plasmin-mediated fibrinolysis if they were added
after clot formation. Contrast agents altered clot
turbidity, an index of fibrin structure, if present
during clot formation, but not if added to preformed
clots. Contrast agents did not affect plasminogen acti-
vator inhibitor-1 or a2-antiplasmin function.
Conclusions: Contrast agents inhibit clot lysis by
inhibiting plasminogen activation and by disrupting
interactions of plasminogen and plasmin with fibrin by
altering fibrin structure. Significant variation in anti-
fibrinolytic properties exists between different
contrast agents.
Abbreviated Abstract. The purpose of this study was
to define specific mechanisms by which contrast agents
inhibit clot lysis. In both a purified clot lysis system
and a plasma clot lysis system, diatrizoate, an ionic
agent, produced the most potent inhibition of fibrino-
lysis. Contrast agents did not inhibit the active sites of
plasminogen activators or plasmin, but did inhibit
plasminogen activation. Binding of plasminogen to
fibrin and lysis of fibrin by plasmin were inhibited by
contrast agents if they were present during clot forma-
tion, but not if they were added after clot formation
was complete. Contrast agents altered clot turbidity, an
index of fibrin structure, if present during clot forma-
tion, but not if added to preformed clots. Contrast
agents did not affect plasminogen activator inhibitor-
1 or a2-antiplasmin function. The effects of contrast
agents on fibrinolytic parameters were not explained
by their high osmolarities. These results suggest that
contrast agents inhibit clot lysis by inhibiting plasmi-
nogen activation and by disrupting interactions of
plasminogen and plasmin with fibrin by altering
fibrin structure.
Key Words. radiographic contrast agents, plasminogen,
fibrinolysis
Radiographic contrast agents are iodinated deri-
vatives of benzoic acid that are used to visualize
arteries, veins, and cardiac chambers during
angiographic procedures. Radiographic contrast
agents inhibit blood coagulation in vitro, with
ionic-type agents producing a greater anticoagu-
lant effect than nonionic-type agents [1]. The
anticoagulant properties of contrast agents
appear to be mediated by multiple mechanisms,
including effects on thrombin formation, fibrin
polymerization, and platelet activation [2–5].
Although controversial, the anticoagulant effect
of contrast agents may influence the frequency of
thrombotic complications during percutaneous
coronary artery interventions [6–9].
Radiographic contrast agents also inhibit fibri-
nolysis. Dehmer et al. showed that plasma clots
formed in the presence of ionic or nonionic
contrast agents were more resistant to lysis by
tissue-type plasminogen activator (t-PA),
urokinase, or streptokinase [10]. Pislaru et al.
demonstrated that iohexol (a low-osmolar non-
ionic agent) and amidotrizoate (a high-osmolar
ionic agent) inhibited coronary thrombolysis in
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dogs, while ioxaglate (a low-osmolar ionic agent)
did not [11]. Contrast agents could inhibit fibri-
nolysis by several potential mechanisms, includ-
ing direct inhibition of plasminogen activators,
inhibition of plasminogen activation, direct inhi-
bition of plasmin, and inhibition of plasmin-
(ogen)-fibrin interactions. Radiographic contrast
agents have also been hypothesized to alter the
function of serine protease inhibitors [12], such as
a2-antiplasmin and plasminogen activator inhibi-
tor-1 (PAI-1), which are known to play a key role
in the regulation of fibrinolysis. However, a
systematic analysis of the effects of radiographic
contrast agents on component reactions of the
fibrinolytic system has not been reported. In
this study, we examined in vitro the effects of 3
commonly utilized radiographic contrast agents
on plasmin formation and activity, plasmin-




Glu-plasminogen was purified from human
plasma [13]. Human fibrinogen, sodium diatrizo-
ate, sodium benzoate, and meglumine were from
Sigma. Plasminogen and fibrinogen were fluores-
cein-labeled as described [14]. 125I-labeled human
fibrinogen was from Amersham Life Sciences.
Streptokinase, urokinase (u-PA), Spectrozyme
UK, Spectrozyme tPA, des-AA-fibrinogen, and
a2-antiplasmin were from American Diagnostica.
Plasmin was prepared by activating plasminogen
with trace u-PA. S-2251 was from Chromogenix.
Human t-PA was from Genentech. Thrombin was
from Calbiochem. Recombinant human PAI-1 was
from Dr. D. Ginsburg, University of Michigan.
Diatrizoate meglumine=diatrizoate sodium
(MD-76), ioversol (Optiray 320), and ioxaglate
meglumine=ioxaglate sodium (Hexabrix) were
from Mallinckrodt Medical.
Clot Lysis Assays
A reconstituted clot lysis assay consisting of
Glu-plasminogen (0.2 mM), fluorescein-labeled
fibrinogen (1 mg=mL), thrombin (2 U=mL), and
t-PA (15 pM) was used. Clots were incubated at
37C and % clot lysis after 45 min was calculated
[14]. Plasma clot lysis assays were performed as
described by Bajzar [15]. Human plasma, CaCl2
(10 mM), thrombin (6 nM), and t-PA (0.6 nM)
were mixed in 96-well microtiter plates. Plates
were incubated at 37C and absorbance at 650 nm
was measured. Lysis time was defined as that
required for clot turbidity to decrease by 50%. To
study the lysis of fibrin by plasmin, citrated
human plasma (500 mL) containing 125I-labeled
fibrinogen (1 mCi) was clotted on polypropylene
rods by adding CaCl2 (25 mM) and thrombin
(1 U=mL). After 45 minutes, clots were washed
 5 with TBS, and clot-bound radioactivity was
measured. Plasmin (0.57 mM in 10 mM Tris-HCl,
150 mM NaCl, pH 7.5 [TBS], total volume 500 mL)
was added, and clots were rocked gently at 37C.
At timed intervals, 5mL of the clot supernatant
was removed and % clot lysis was calculated from
the ratio of supernatant radioactive counts to
washed clot counts.
Enzyme Activity Assays
Amidolytic activities of t-PA (3.5 nM), u-PA
(50 U=mL), and plasmin (10 nM) were determined
by incubating each enzyme in TBS, 0.1% BSA
(TBS=BSA) containing synthetic substrate (Spec-
trozyme tPA, Spectrozyme UK, or S-2251, each at
300 mM) and monitoring absorbance at 405 nm.
Enzyme activities were determined from stan-
dard curves for each protease. Plasminogen
activation in TBS=BSA was studied by incubating
plasminogen (1 mM) and S-2251 (300mM) with
u-PA, streptokinase, or t-PA and des-AA-fibrino-
gen. Plasminogen activation in citrated plasma
was studied by adding S-2251 (300 mM), des-AA-
fibrinogen (0.1 mM), and t-PA and monitoring
absorbance at 405 nm. The effects of contrast
agents on the inhibitory activities of a2-antiplas-
min and PAI-1 were studied as described [16].
Binding of Plasminogen to Fibrin
Fibrin-coated microtiter plate wells (96-well)
were prepared by incubating fibrinogen (1.5 mM)
and thrombin (2 U=mL) in 100mL of TBS and air
drying plates [5]. Wells were blocked with 3%
BSA and washed. Fluorescein-labeled plasmino-
gen (0–2.2 mM) and radiographic contrast agent
(2.5%) in 100 mL of TBS=BSA were added to wells
and incubated at 37C for 30 minutes. Wells were
washed 5 times, and bound plasminogen was
eluted by adding 1% SDS (100 mL) and incubating
plates at 37C for 1 hr. Eighty mL were removed
and fluorescence was measured [14]. To study
plasminogen binding to forming clots, contrast
agents and fluorescein-labeled human plasmino-
gen (2.2 mM) were added to citrated human
plasma (total volume 500 mL) and clotting was
initiated with CaCl2 and thrombin. Retracted
clots were washed  5, blotted dry, weighed,
then lysed completely by addition of TBS contain-
ing t-PA (15 nm) and unlabeled plasminogen
(1.1 mM). Fluorescence was measured and
divided by clot weight to determine clot-bound
plasminogen.
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Clot Turbidity Assay
Citrated human plasma (92.5 mL) containing
contrast agent (2.5%) or an equal volume of
TBS was placed in microtiter wells and thrombin
(0.25 U=mL) was added. Turbidity of forming
clots was monitored at 608 nm. Maximum turbid-
ity minus turbidity prior to clot formation was
used as an index of fibrin fiber density [17–19]. In
separate experiments, plasma clots (975 mL) were
formed in quartz cuvettes in the absence of
contrast agents. After maximum clot turbidity
was achieved (approximately 15 minutes), clots
were overlaid with 1 mL of 10% diatrizoate and
turbidity at 608 nm was monitored for 8 hrs. With
each experiment, an identical control clot was
overlaid with 10% diatrizoate containing 0.05%
methylene blue to allow visual confirmation that
the overlaid solution completely perfused the clot.
Statistical Analysis
Data are presented as mean  1 standard error of
the mean (SEM), unless otherwise indicated. The
Student’s t test or the Mann-Whitney Rank Sum
test was used to compare experimental groups.
Results
Effects of Radiographic Contrast Agents on
Clot Lysis
We incubated fluorescein-labeled fibrinogen,
plasminogen, t-PA, and thrombin in the presence
of contrast agent (2.5%) or TBS, then monitored
clot lysis (Fig. 1A). Diatrizoate (MD-76), a high
osmolar ionic agent, inhibited clot lysis by
81.3 0.6% (p< 0.001 vs. control). Ioxaglate, a
low osmolar ionic agent, inhibited clot lysis by
41.7 11.9% compared to control, but this did not
achieve statistical significance (p¼ 0.07). Iover-
sol, a nonionic agent, did not significantly inhibit
clot lysis (14.9 11.5% decrease in lysis vs.
control; p> 0.3). Isosomolar sucrose and=or
NaCl solutions did not significantly affect clot
lysis (diatrizoate control was 2 M sucrose,
77 mM NaCl; ioxaglate control was 300 mM
Fig. 1. Inhibition of clot lysis by radiographic contrast agents. A. Fluorescein-labeled fibrin clots were incubated with t-PA and
plasminogen in the presence of radiographic contrast agents (2.5%, black bars) or equal volumes of isosmolar sucrose=NaCl
solutions (white bars) or Tris-buffered saline (TBS). Amounts of clot lysis after 45 min are shown. Results are expressed as ratio of %
lysis of clots formed in the presence of contrast agent or osmolar control solution to % lysis of clots formed in presence of TBS. Data
are mean of triplicate experiments. B. Plasma clots were formed in the presence of radiographic contrast agents (2.5% concentration)
or an equal volume of TBS. Clot lysis times were measured. Data represent mean of  4 experiments.
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Fig. 2. Effects of radiographic contrast agents on enzyme amidolytic activity. T-PA (3.5 nm, A), u-PA (50 U=mL, B), or plasmin
(10 nm, C) were incubated with radiographic contrast agents and amidolytic activities were measured. Data points represent mean
of  3 experiments 1 standard deviation. Diamonds, diatrizoate; triangles, ioversol; squares, ioxaglate.
Fig. 3. Effects of radiographic contrast agents on plasminogen activation. Glu-plasminogen (1 mM), S-2251 (300mM), and
radiographic contrast agents were incubated with t-PA (3 nm, A), u-PA (10 U=mL, B), or streptokinase (0.8 U=mL, C) and plasmin
formation was monitored. Data points represent mean of 3 experiments  1 standard deviation. Diamonds, diatrizoate; triangles,
ioversol; squares, ioxaglate. D. Osmolar effects of contrast agents on plasminogen activation. T-PA (3 nm), Glu-plasminogen (1mM),
des-AA fibrinogen (100 nm), and S-2251 (300mM) were incubated with 5% contrast agent (black bars) or equal volumes of isosmolar
sucrose=NaCl solutions (white bars, see text for details). Plasmin formation was monitored and expressed as % of control reactions
performed in presence of equal volumes of Tris-buffered saline.
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NaCl; ioversol control was 0.7 M sucrose). We also
studied the antifibrinolytic properties of the indi-
vidual components of MD-76, which is a mixture
of sodium diatrizoate and meglumine diatrizoate.
Sodium diatrizoate (15 mg=mL, i.e. concentration
yielding same amount of organically bound iodine
as 2.5% MD-76) inhibited clot lysis by 67%.
Meglumine (4 mg=mL), an organic cation, inhibi-
ted clot lysis by only 8%. Sodium benzoate
(3.3 mg=mL), the noniodinated parent molecule
of sodium diatrizoate, inhibited clot lysis by 72%.
These results suggested that the antifibrinolytic
effect of MD-76 was attributable to its sodium
diatrizoate content, but did not depend on its
iodine content or its high osmolarity. To deter-
mine the effects of contrast agents on fibrinolysis
in a plasma environment, we formed plasma clots
in the presence of diatrizoate, ioxaglate, ioversol
(each at 2.5%), or TBS, then measured the
time until 50% clot lysis (Fig. 1B). Diatrizoate
markedly inhibited fibrinolysis (lysis time
184 10.7 min vs. 23.9 6.7 min for TBS control,
p¼ 0.01). Ioxaglate did not significantly prolong
clot lysis (lysis time 30.8 4.9 min; p> 0.15 vs.
TBS control). Ioversol prolonged the clot lysis
time to 76.0 6.4 min, which was of borderline
statistical significance (p¼ 0.07 vs. control).
Isosmolar control solutions did not inhibit
plasma clot lysis (data not shown).
Effects of Contrast Agents on Fibrinolytic
Proteases and Inhibitors
T-PA amidolytic activity was not inhibited by
diatrizoate or ioversol, while ioxaglate produced
a mild inhibitory effect (Fig. 2). U-PA and plasmin
amidolytic activities were not inhibited by
contrast agents. However, activation of Glu-
plasminogen by t-PA, u-PA, or streptokinase was
inhibited by each agent (Fig. 3). The inhibition
of Glu-plasminogen activation by contrast agents
was not mediated to a significant extent by their
osmolar properties (Fig. 3D). Sodium diatrizoate
(30 mg=mL) and sodium benzoate (6.6 mg=mL)
inhibited t-PA-catalyzed plasminogen activation
by 41% and 53%, respectively. The activation of
plasminogen in citrated plasma by pharmacologic
concentrations of t-PA (1 mg=mL) was inhibited
58.7 5%, 59.6 0.7%, and 63.9 2.1% by
diatrizoate, ioxaglate, and ioversol (each at
2.5%), respectively. Diatrizoate, ioxaglate, and
ioversol (each at 2.5%) had no significant effect
Fig. 4. Effects of radiographic contrast agents on plasmin(ogen)-fibrin interactions. A. Binding of plasminogen to fibrin. Citrated
plasma was clotted in the presence of fluorescein-labeled plasminogen (200 mg=mL) and radiographic contrast agent (5%) or an equal
volume of Tris-buffered saline (Control). Clots were washed extensively and bound fluorescence per gram of clot was measured. Data
represent mean of 4 experiments. Results statistically different from control are designated by ‘‘*’’ (p< 0.01) and ‘‘**’’ (p< 0.001). B.
Digestion of fibrin by plasmin. Plasma clots were formed in the presence of 125I-labeled fibrinogen and radiographic contrast agent
(5%) or an equal volume of Tris-buffered saline (Control). After extensively washing clots, plasmin was added and % clot lysis was
measured 30 min (white bars) and 60 min (black bars) later. Data represent mean of 6 experiments. Results statistically different
from control are designated by ‘‘*’’ (p< 0.05).
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on the capacity of a2-antiplasmin or PAI-1 to inhi-
bit plasmin or t-PA, respectively (data not shown).
Effect of Contrast Agents on
Fibrin-Plasmin(ogen) Interactions
To test the hypothesis that modification of fibrin
by contrast agents inhibits plasmin(ogen)-fibrin
interactions, we formed plasma clots in the
presence of fluorescein-labeled plasminogen and
radiographic contrast agent (5%), then measured
clot-bound plasminogen (Fig. 4A). Diatrizoate
inhibited plasminogen binding by 51 3.8%
compared to control (p< 0.001), while ioxaglate
inhibited plasminogen binding by 30.1 4.2%
(p< 0.01). Ioversol did not significantly inhibit
plasminogen binding (19.4 6.6% reduction
compared to control, p> 0.06). Sucrose=NaCl
solutions with the same osmolarity as each
contrast agent did not inhibit binding of plasmi-
nogen to clots (data not shown). Diatrizoate (10%)
did not displace plasminogen from lysine-
Sepharose (data not shown), suggesting that the
inhibition of plasminogen binding to fibrin clots
was not mediated by an epsilon-aminocaproic
acid (EACA)-like effect. We also examined the
effects of contrast agents on plasmin-mediated
fibrinolysis (Fig. 4B). Diatrizoate inhibited clot
lysis at 60 minutes by 40 5.7% compared to
control (p< 0.03), while ioxaglate and ioversol
Fig. 5. Effects of radiographic contrast agents on clot turbidity. A. Thrombin was added to plasma in the presence of 2.5%
diatrizoate (diamonds), ioxaglate (squares), ioversol (triangles), or Tris-buffered saline (TBS, circles), and clot turbidity was
monitored. B–D. Comparison of effects of diatrizoate (B), ioxaglate (C), and ioversol (D) to those of their respective isosmolar
sucrose=NaCl solutions (see text for details). Open diamonds, squares, or triangles represent each contrast agent (2.5%
concentration). Filled diamonds, squares, or triangles represent 2.5% concentrations of appropriate isosmolar control solution.
Circles represent TBS.
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had no significant effect. However, if fibrin clots
were formed in the absence of contrast agents,
then incubated with plasmin or fluorescein-
labeled plasminogen in the presence of contrast
agents (2.5%), fibrinolysis and plasminogen
binding were not inhibited (data not shown),
suggesting that modification of clot structure
during fibrin formation was necessary for
contrast agents to inhibit fibrin-plasmin(ogen)
interactions.
Effects of Radiographic Contrast Agents on
Clot Turbidity
The maximum turbidities of clots formed in the
presence of diatrizoate, ioxaglate, or ioversol
(each at 2.5%) were 42%, 65%, and 43% that of
control clots (Fig. 5A), suggesting that each
contrast agent induced formation of thinner
fibrin fibers, with ioxaglate producing the least
perturbation in fibrin structure. A sucrose=NaCl
solution with the same osmolarity as diatrizoate
produced only a minor effect on clot turbidity,
while the osmolar control solutions for ioxaglate
and ioversol exerted no significant effects
(Fig. 5B–D). The turbidity of plasma clots
formed in the absence of contrast agents, then
incubated in the presence of 10% diatrizoate for
8 hrs decreased by < 5%, suggesting that fibrin
structure was not altered by diatrizoate if it was
added after clot formation was complete.
Discussion
Our studies demonstrate that contrast agents
inhibit fibrinolysis by multiple mechanisms, and
that the antifibrinolytic properties of different
classes of contrast agents vary significantly. The
antifibrinolytic properties of contrast agents have
been attributed to their high osmolarities [11].
However, our results suggest that the effects of
contrast agents on clot lysis are not mediated by
their high osmolarities, but rather by specific,
iodine-independent, chemical properties. Inhibi-
tion of clot lysis by contrast agents did not appear
to result from interactions with the active-sites of
plasminogen activators or plasmin. However,
contrast agents inhibited plasminogen activation
in a concentration-dependent manner. Our
results are consistent with those of Schilvold
et al. [20]. However, these studies involved signif-
icantly higher concentrations of contrast agents
than our experiments, did not examine plasmino-
gen activation in plasma, and did not investigate
the osmolar effects of contrast agents on plasmi-
nogen activation. Previous studies demonstrated
that contrast agents inhibit the capacity of plas-
minogen activators to lyse fibrin clots [10,21].
However, in these experiments it was not pos-
sible to differentiate effects of contrast agents on
plasminogen activation from ‘‘downstream’’
effects on the lysis of fibrin by plasmin. Our
experiments show that clots formed in the
presence of contrast agents, particularly diatrizo-
ate, are resistant to lysis by plasmin. Since plas-
min activity was not inhibited by contrast agents,
their capacity to inhibit clot lysis is most likely
explained by a direct effect on fibrin. Our studies
of clot turbidity suggested that the contrast
agents used in our experiments modified fibrin
structure, with diatrizoate and ioversol exerting
greater effects than ioxaglate. These changes are
consistent with earlier studies demonstrating
that contrast agents induce formation of fibrin
fibers with lower mass-length ratios [22,23].
However, a functional consequence (i.e. reduced
sensitivity to lysis by plasmin) of contrast-
induced changes in fibrin structure has not been
demonstrated previously. In addition, we showed
that clots formed in the presence of contrast
agents, particularly diatrizoate, demonstrate
reduced plasminogen binding capacity. This may
represent an important mechanism by which
contrast agents downregulate fibrinolysis, since
plasminogen recruitment to fibrin is a critical
determinant of clot lysis [24,25]. However, our
results suggested that clot structure, capacity to
bind plasminogen, and sensitivity to lysis by
plasmin were altered by contrast agents only if
they were present during clot formation. These
data support the hypothesis that radiographic
contrast agents modify fibrin by affecting its
polymerization, but do not significantly affect the
structure or sensitivity to lysis of preformed clots.
It therefore appears that radiographic contrast
agents can inhibit both blood coagulation and
fibrinolysis, with ionic agents generally produ-
cing a more potent effect on both processes than
nonionic agents do. It is reasonable to hypothe-
size that the ratio of the anticoagulant effect to
antifibrinolytic effect of a contrast agent deter-
mines its net antithrombotic effect. It is of interest
that ioxaglate, a low osmolar ionic agent,
produced the least inhibition of plasma clot lysis
and the least perturbation of fibrin fiber density,
since in previous studies we found that ioxaglate
(in comparison to diatrizoate and ioversol)
produced the most potent inhibition of throm-
bin generation. Thus, ioxaglate exhibits the
highest ratio of anticoagulant=antifibrinolytic
effects— i.e. the least thrombogenic profile. This
observation is consistent with clinical studies
suggesting that ioxaglate is associated with a
lower risk of thrombosis during coronary angio-
plasty than nonionic contrast agents are
[6–8,26,27]. Although the relative antithrombotic
effects of ioxaglate observed in these trials may
be explained by its more potent inhibition of blood
coagulation, the relative lack of inhibition of clot
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lysis by ioxaglate compared to other contrast
agents could also contribute to its apparent clin-
ical benefits.
Although our studies identify potential mech-
anisms by which contrast agents may modulate
fibrinolysis, several factors must be taken into
account when considering their clinical signifi-
cance. Our experiments did not examine the
potential effects of contrast agents on coronary
blood flow, platelets, and vascular endothelial
cells, all of which can modulate thrombolysis. In
addition, our experiments used steady-state
concentrations of contrast agents. During angio-
graphy the concentration of contrast agents in
the coronary circulation varies substantially.
Plasma levels are very high for several seconds
during contrast injection, but decay rapidly in the
absence of coronary occlusion. Although adult
patients may receive as much as 200 mL of
contrast agent during cardiac catheterization,
the circulating concentration of contrast agents
between injections is probably less than 2% [28].
Nevertheless, Dehmer et al. demonstrated that
plasma clots prepared from peripheral blood
samples obtained at the completion of catheter-
ization procedures were resistant to lysis in vitro,
suggesting that even low concentrations of
contrast agents can affect clot lysis [10]. In addi-
tion, Pislaru et al. demonstrated that contrast
agents inhibit of t-PA-mediated coronary throm-
bolysis in dogs [11]. Even minor effects of contrast
agents on fibrinolysis could potentially influence
the results of clinical trials in which thrombolytic
drug efficacy is determined by serial injections of
contrast agents into an occluded coronary artery
in order to determine the time required to restore
patency. Therefore, it may be important for these
types of angiographic studies to rigorously stan-
dardize the type and amount of contrast agent
that is administered after infusion of the throm-
bolytic drug.
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